Phase 3 study of IV lasmiditan in migraine patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 May 2016 New trial record
11 May 2016 According to CoLucid Pharmaceuticals media release, company has filed an Investigational New Drug application (IND) with the FDA for IV lasmiditan and the company's clinical program may proceed when it manufactures its IV product under the FDA's current Good Manufacturing Practices (cGMP) and it submits a certificate of analysis (COA). Company has also received preliminary feedback on this trial and will be resubmitted under a request for SPA in parallel to the submission of the COA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com